ReviewCurrent cardiology reports2023
Recent Advances in Serum Biomarkers for Risk Stratification and Patient Management in Cardio-Oncology.
Review in Current cardiology reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 28 citations in OpenAlex.
- The Overlay of Cervical Cancer with Cardiac Metastasis.Cardiology · 2026Pooled it
- Early diagnostic value of novel biomarkers for breast cancer therapy-related cardiac dysfunction.ESC heart failure · 2025Pooled it
- Non-Oncology Biomarkers in Precision Medicine: A Narrative Review.Therapeutic innovation & regulatory science · 2026Review
- A Hidden Indicator of Cardiovascular Health: Serum Gamma-Glutamyl Transferase in Focus.Journal of cardiovascular translational research · 2026Review
- Longitudinal Trends in Myocardial Metabolic Uptake Following Stereotactic Arrhythmia Radioablation Using 2-Deoxy-2-[International journal of radiation oncology, biology, physics · 2026Article
- Heart Substructure Radiation Dose and Cardiac Outcomes: Contemporary Evidence and Actionable Opportunities: JACC CardioOncology State-of-the-Art Review.JACC. CardioOncology · 2026Review
- Imaging-based detection and prediction of radiation-induced cardiac toxicity: a narrative review.BJR open · 2026Review
- A serum biomarker panel for early detection of treatment-related cardiotoxicity in early HER2-positive breast cancer patients.Annals of medicine and surgery (2012) · 2025Article
- Anthracycline- and HER2-induced cardiotoxicity: mechanisms, current strategies, and the emerging role of dapagliflozin as a targeted cardioprotective agent.Cardio-oncology (London, England) · 2025Review
- Emerging Strategies for the Prevention of Chemotherapy-Induced Cardiotoxicity in Paediatric Cancer Patients: Advances and Future Perspectives.Pharmaceuticals (Basel, Switzerland) · 2025Review
- High-Sensitivity Troponin I: The Optimal Biomarker for Anthracycline Cardiotoxicity?JACC. CardioOncology · 2025Article
- Novel cardiac biomarkers and multiple-marker approach in the early detection, prognosis, and risk stratification of cardiac diseases.World journal of cardiology · 2025Review
- Cardiovascular Toxicity in Patients Treated for Childhood Cancer: A Scientific Statement From the American Heart Association.Circulation · 2025Review
- Artificial Intelligence to Enhance Precision Medicine in Cardio-Oncology: A Scientific Statement From the American Heart Association.Circulation. Genomic and precision medicine · 2025Review
- Cardiotoxicity following thoracic radiotherapy for lung cancer.British journal of cancer · 2025Review
- Evaluating high-sensitivity cardiac troponin I for early detection of treatment-related cardiotoxicity in HER2-positive breast cancer patients.Annals of medicine and surgery (2012) · 2025Article
- Life expectancy in cancer patients with pulmonary thromboembolism: From clinical prognostic biomarkers and paraclinical investigations to therapeutic approaches (Review).Experimental and therapeutic medicine · 2024Review
- Applied Cardio-Oncology in Hematological Malignancies: A Narrative Review.Life (Basel, Switzerland) · 2024Review
- Article
- Anthracycline's Effects on Heart Rate Variability in Children with Acute Lymphoblastic Leukemia: Early Toxicity Signs-Pilot Study.Journal of clinical medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
purpose of reviewFollowing significant advancements in cancer therapeutics and survival, the risk of cancer therapy-related cardiotoxicity (CTRC) is increasingly recognized. With ongoing efforts to reduce cardiovascular morbidity and mortality in cancer patients and survivors, cardiac biomarkers have been studied for both risk stratification and monitoring during and after therapy to detect subclinical disease. This article will review the utility for biomarker use throughout the cancer care continuum. RECENT
findingsA recent meta-analysis shows utility for troponin in monitoring patients at risk for CTRC during cancer therapy. The role for natriuretic peptides is less clear but may be useful in patients receiving proteasome inhibitors. Early studies explore use of myeloperoxidase, growth differentiation factor 15, galectin 3, micro-RNA, and others as novel biomarkers in CTRC. Biomarkers have potential to identify subclinical CTRC and may reveal opportunities for early intervention. Further research is needed to elucidate optimal biomarkers and surveillance strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.